Keyphrases
Non-small Cell Lung Cancer (NSCLC)
62%
Lung Cancer
53%
Tumor
41%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
40%
Non-small Cell Lung Cancer Patients
25%
Overall Survival
20%
Targeted Therapy
18%
Epidermal Growth Factor Receptor
17%
Chemotherapy
15%
Confidence Interval
13%
Small Cell Lung Cancer
13%
Lung Cancer Patients
12%
Lung
12%
Early-stage Lung Cancer
12%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
11%
Adenocarcinoma
11%
Nude Mice
11%
Progression-free Survival
11%
Clinical Trials
11%
Human Lung Cancer
10%
Lung Cancer Screening
10%
EGFR mutation
10%
Paclitaxel
10%
Tumor Cells
10%
Immune Checkpoint Inhibitors
10%
Growth Factors
9%
Gefitinib
9%
Comorbidity
9%
Israel
9%
Adverse Events
8%
Radiotherapy
8%
Pleural Effusion
8%
Cancer Patients
8%
Orthotopic Model
7%
Asthma
7%
Metastasis
7%
Bronchioloalveolar Carcinoma
7%
Targeted Treatment
7%
Immunohistochemistry
7%
Platelet-derived Growth Factor Receptor (PDGFR)
7%
Patient Survival
7%
Vascular Endothelial Growth Factor
7%
Poor Outcome
7%
Long-term Survival
7%
Induced Sputum
6%
Stable Disease
6%
Melanoma Cells
6%
Chest CT
6%
Tumor Growth
6%
Metastatic Non-small Cell Lung Cancer
6%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Lung Cancer
64%
Neoplasm
61%
Epidermal Growth Factor Receptor
35%
Malignant Neoplasm
24%
Disease
21%
Targeted Therapy
19%
Adenocarcinoma
16%
Overall Survival
15%
Radiation Therapy
14%
Immunotherapy
14%
Metastatic Carcinoma
13%
Tumor Cell
10%
Computer Assisted Tomography
10%
Cancer Cell
10%
Recurrent Disease
9%
Biological Marker
9%
Small Cell Lung Cancer
9%
Immune Checkpoint Inhibitor
9%
Lung Adenocarcinoma
8%
Vasculotropin
8%
Transcriptomics
7%
Asthma
7%
Patient Referral
7%
Clinical Trial
7%
Platelet Derived Growth Factor Receptor
7%
Cancer Therapy
7%
Long Term Survival
6%
Lung Alveolus Cell Carcinoma
6%
Melanoma Cell
6%
Chemoradiotherapy
6%
Angiogenesis Inhibitor
6%
Progression Free Survival
6%
Lung Transplantation
6%
Adverse Event
6%
Liquid Biopsy
6%
COVID-19
6%
Malignant Pleural Effusion
6%
Nivolumab
6%
Imatinib
6%
Disease Marker
5%
Biopsy
5%
Systemic Therapy
5%
Immunohistochemistry
5%
Tumor Progression
5%
Low Drug Dose
5%
In Vitro
5%
Growth Factor
5%
microRNA
5%
Epidermal Growth Factor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
73%
Lung Cancer
63%
Neoplasm
51%
Malignant Neoplasm
33%
Epidermal Growth Factor Receptor
30%
Chemotherapy
22%
Disease
18%
Immunotherapy
14%
Nude Mouse
14%
Overall Survival
13%
Mouse
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Gefitinib
10%
Adenocarcinoma
9%
Small Cell Lung Cancer
9%
Clinical Trial
9%
Protein Tyrosine Kinase Inhibitor
8%
Progression Free Survival
8%
Adverse Event
8%
Melanoma
8%
Paclitaxel
8%
Tumor Growth
8%
Metastasis
7%
Vasculotropin
7%
Erlotinib
7%
Mouse Model
7%
Long Term Survival
6%
Angiogenesis Inhibitor
6%
Protein Tyrosine Kinase
6%
Platelet Derived Growth Factor Receptor
6%
Imatinib
6%
Immune Checkpoint Inhibitor
5%
Solid Malignant Neoplasm
5%
Biological Marker
5%
Growth Factor
5%
Lung Adenocarcinoma
5%
Vandetanib
5%